Role of maternal immune activation in neurodevelopment disorders and possible pharmacological treatment
Aberrant immune activity during vulnerable and critical periods of neurodevelopment could participate in the generation of neurological dysfunction characteristic of several neurodevelopmental disorders (NDDs), including autism spectrum disorders and schizophrenia. Numerous epidemiological studies have shown a link between maternal infections and NDDs risk; animal models of Maternal Immune Activation (MIA) have confirmed this association. No current therapy exists for treatment or prevention of ASD. Drugs currently used for ASD are mainly symptomatic lacking specificity and are often ineffective for behavioural deficits. In order to find new drug therapy that acts on causes of ASD not on symptoms, a nonsteroidal anti-inflammatory drug, was used.